Source
111 developments in the corpus
Latest
Everything in the corpus, newest first.
OCT 23, 2026 · JOURNAL ARTICLE
Cancers
Background/Objectives: Cancer survivors frequently experience long-term neurocognitive impairments following chemotherapy and cranial irradiation, yet experimental models that enab
OCT 23, 2026 · JOURNAL ARTICLE
Cancers
Background: Outcomes for advanced or recurrent endometrial cancer (EC) remain poor, with historically limited systemic options beyond platinum-based chemotherapy. EC is uniquely im
OCT 23, 2026 · JOURNAL ARTICLE
Cancers
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. Immune checkpoint inhibitor (ICI)-based combinations have become the standard first-line systemic the
OCT 23, 2026 · JOURNAL ARTICLE
Cancers
Background/Objectives: Medullary thyroid cancer (MTC) is a rare but aggressive neuroendocrine malignancy arising from parafollicular C cells. Despite its low incidence, MTC has his
OCT 22, 2026 · JOURNAL ARTICLE
Cancers
Background/Objectives: Bone metastasis (BM) occurs in approximately 70% of patients with advanced breast cancer (BCa) and is associated with limited treatment options and a median
OCT 22, 2026 · JOURNAL ARTICLE
Cancers
The gut microbiome influences colorectal cancer (CRC) progression and responses to immune checkpoint inhibitors (ICIs), with immunotherapy resistance remaining a major challenge in
OCT 22, 2026 · JOURNAL ARTICLE
Cancers
Background: Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer and is characterized by the loss of E-cadherin resulting from alteratio
OCT 21, 2026 · JOURNAL ARTICLE
Cancers
Triple-negative breast cancer (TNBC) is characterised by the absence of expression of oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor recepto